




BD PureHub™ Disinfecting Cap

Optimally designed to help optimize outcomes




Clear Evidence: Contaminated IV access points are portals for infection


Consider the impact of central line-associated bloodstream infection (CLABSI)



Up to **90%** of hospital inpatients **require IV therapy**¹



Central venous catheters are reported to be one of the **most frequent causes** of healthcare-associated bloodstream infections²



30,100 CLABSIs still occur in intensive care units and the wards of U.S. acute care facilities each year³



The Centers for Disease Control estimates that the **annual cost of CLABSI** is more than **\$1 BILLION**²

Expert clinical guidelines support the use of **disinfecting caps**



2014 SHEA* Compendium⁴

If CLABSI surveillance or other risk assessments suggest that there are **ongoing opportunities for improvement**, hospitals should then consider adopting some or all the prevention approaches listed as special approaches. Among the **special approaches listed**: Use an antiseptic-containing hub/connector cap/port protector to cover connectors.



The Joint Commission CRBSI[†] Toolkit: Valve disinfection guidance²

If you continue to have a high rate of infections, **consider using alcohol-impregnated port protectors**, scrubbing devices and needleless neutral displacement connectors in addition to scrubbing the hub.



Infusion Nursing Standards of Practice⁵

Disinfecting caps containing 70% isopropyl alcohol are supported by the Infusion Nursing Society 2021 guidelines for passive disinfection of needle-free connectors.

Active disinfection with alcohol-based chlorhexidine gluconate swab pads or **passive disinfection with caps containing 70% isopropyl alcohol were associated with lower rates of CLABSI**, while swab pads containing 70% isopropyl alcohol were the least effective according to a meta-analysis of quasi-experimental studies.

Royal College of Nursing

The Royal College of Nursing Infusion Therapy Standards⁶

Use of passive disinfectant caps containing agents (such as isopropyl alcohol) should be in line with local policies.

* SHEA: Society for Healthcare Epidemiology of America

† CRBSI: Catheter-Related Bloodstream Infection

BD PureHub™ Disinfecting Cap is designed for rapid disinfection and secure protection



And optimized to fit market-leading needle-free connectors

Meets ISO performance standards for luer design compatibility

Intended use

BD PureHub™ Disinfecting Cap is intended to be used as a disinfecting device for swabbable needle-free luer connectors prior to access and to act as a physical barrier between line accesses.



Efficacy

- Rapid disinfection in just 1 minute
- Disinfects with a sterilized 70% isopropyl alcohol solution
- Provides a >4 log (99.99%) reduction in bacteria*

Security

- Brightly colored BD PureHub™ Disinfecting Cap provides visual confirmation of compliance with disinfection protocol
- Maintains a physical barrier to contamination for up to 7 days, if not removed**

Easy to use

- Large width and finger grips for ease of application and removal
- Easy to apply with uniquely designed luer threads
- Designed for compatibility with market leading needle-free connectors, including BD MaxZero™, BD SmartSite™ and BD Q-Syte™ Needle-Free Connectors

Warning: 70% Isopropyl Alcohol is not considered sporicidal and may not prevent Central Line-Associated Blood Stream Infection arising from bacterial spores (e.g., Bacillus spp., Clostridia)

* Demonstrated reduction on *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Pseudomonas aeruginosa*, *Escherichia coli*, *Candida glabrata*, *Candida albicans* and *Acinetobacter baumannii* as tested in a laboratory.

† As demonstrated through in vitro studies.

‡ Bench Test results may not necessarily be indicative of clinical performance.



BD PureHub™ Disinfecting Cap delivers antimicrobial performance

Tested for effectiveness

BD PureHub™ Disinfecting Cap demonstrated in a laboratory a **99.99% (>4 log) reduction** on the most common causative agents in CRBSI including:

Staphylococcus aureus, *Staphylococcus epidermidis*, *Pseudomonas aeruginosa*, *Escherichia coli*, *Candida glabrata*, *Candida albicans*, *Acinetobacter baumannii*.*




Staphylococcus aureus



Staphylococcus epidermidis




Escherichia coli



Acinetobacter baumannii



Pseudomonas aeruginosa



Candida glabrata



Candida albicans

BD PureHub™ Disinfecting Cap demonstrated reduction of *Acinetobacter baumannii*

A. baumannii is **the third most common gram-negative pathogen** responsible for hospital-acquired infections (HAIs)⁷

- BD PureHub demonstrated to reduce *A. baumannii* by 99.99%*
- It is one of **the most common HAIs in children across the U.S.** and is on the rise⁸
- *A. baumannii* accounts for **15%** of CLABSIs reported in one study⁹
- *A. baumannii* is introduced to a hospital by a colonized patient
- *A. baumannii* can be spread by person-to-person contact or contact with contaminated surfaces and can enter through open wounds, catheters and breathing tubes

* Bench Test results may not necessarily be indicative of clinical performance.

Part of the full BD Vascular Access Management (VAM) portfolio

Designed to help reduce complications

BD Vascular Access Management is an integrated approach designed to help reduce vascular access-related complications that may help improve patient care.

The BD Vascular Care Solution, which included BD PureHub™ Disinfecting Cap, BD PosiFlush™ Prefilled Syringe, MaxZero™ Needle-free Connector, and BD Nexiva™ PIV Catheter, **reduced the relative risk of PIVC failure by 27%** as compared with the standard approach.* This BD Vascular Care Solution is also **significantly more effective to reduce PVC-complications** when compared to the standard devices approach, with significant cost savings for the hospital.^{10,11}



* Standard group includes Insyte Autoguard, three-way stopcock, sterile gauze and alcohol-based antiseptic, gravity saline/polyionic solution infusion.

BD PureHub™ Disinfecting Cap ordering information

Material number	Description	Packaging	Units per box	Units per case
306596	BD PureHub™ Disinfecting Cap	Singles	300	3,000 (10 boxes)
306597	BD PureHub™ Disinfecting Cap	Strips (10 count)	30 strips	4,500 (15 boxes)



References

1. RE, Klausner JD, Klemperer JD, Flint LM, Huang E. Accepted but unacceptable: peripheral IV catheter failure. *J Infus Nurs.* 2015;38(3):189-203.
2. The Joint Commission. CLABSI infographic. <https://www.jointcommission.org/resources/patient-safetytopics/infection-prevention-and-control/central-line-associatedbloodstream-infections-toolkit-and-monograph/>. Accessed November 7, 2022.
3. Centers for Disease Control. National and State Healthcare-Associated Infections Progress Report. Published October 2019. <https://www.cdc.gov/hai/data/portal/progress-report.html>. Accessed November 7, 2022.
4. Marschall J, Mermel LA, Fakih M, et al. Strategies to prevent central line associated bloodstream infections in acute care hospitals: 2014 update. *Infect Control Hosp Epidemiol.* 2014;35(7):753-771.
5. Gorski LA, Hadaway L, Hagle ME, Broadhurst D, et al. Infusion therapy standards of practice. *J Infus Nurs.* 2021;44 (suppl 1S):S1-S231.
6. Royal College of Nursing. Standards for infusion therapy, 4th ed. London, UK: RCN IV Therapy Forum; 2016.
7. Drexel University College of Medicine. Department of Surgery: Surgical Infections Research. <https://drexel.edu/medicine/about/departments/surgery/research/surgical-infections-research/>. Accessed October 17, 2018.
8. Logan LK, Gandra S, Trett A, Weinstein RA, Laxminarayan R. Acinetobacter baumannii resistance trends in children in the United States, 1999. *J Pediatr Infect Dis Soc.* 2019;8(2):136-142.
9. Mittal G, Gaiind R, Verma PK, Deb M. Central venous catheter-related bloodstream infections in an intensive care unit from a tertiary care teaching hospital in India. *Int J Infect Control.* 2016;12(1):1-6.
10. Guenezan J, Marjanovic N, Drugeon B, et al. Chlorhexidine plus alcohol versus povidone iodine plus alcohol, combined or not with innovative devices, for prevention of short-term peripheral venous catheter infection and failure (CLEAN 3 study): an investigator-initiated, open-label, single centre, randomised-controlled, two-by-two factorial trial. *Lancet Infect Dis.* 2021;21(7):1038-1048.
11. Maunoury F, Drugeon B, Boisson M, et al. Cost-effectiveness analysis of bundled innovative devices versus standard approach in the prevention of unscheduled peripheral venous catheters removal due to complications in France. *PLoS One.* 2022;17(6):e0269750.